Envestnet Portfolio Solutions Inc. Sells 636 Shares of Agilent Technologies, Inc. (NYSE:A)

Envestnet Portfolio Solutions Inc. lessened its holdings in Agilent Technologies, Inc. (NYSE:A) by 1.9% in the second quarter, Holdings Channel reports. The institutional investor owned 33,025 shares of the medical research company’s stock after selling 636 shares during the period. Envestnet Portfolio Solutions Inc.’s holdings in Agilent Technologies were worth $4,281,000 at the end of the most recent quarter.

Several other hedge funds have also added to or reduced their stakes in the business. Livelsberger Financial Advisory bought a new stake in shares of Agilent Technologies in the 4th quarter valued at about $26,000. VisionPoint Advisory Group LLC bought a new stake in Agilent Technologies in the fourth quarter valued at approximately $29,000. Rise Advisors LLC boosted its holdings in Agilent Technologies by 527.8% in the first quarter. Rise Advisors LLC now owns 226 shares of the medical research company’s stock valued at $33,000 after acquiring an additional 190 shares during the last quarter. YHB Investment Advisors Inc. bought a new position in Agilent Technologies during the 1st quarter worth approximately $34,000. Finally, Riverview Trust Co acquired a new position in shares of Agilent Technologies in the 1st quarter worth approximately $41,000. 87.42% of the stock is currently owned by institutional investors and hedge funds.

Agilent Technologies Stock Up 2.2 %

NYSE A traded up $3.04 on Thursday, reaching $139.07. The company had a trading volume of 422,674 shares, compared to its average volume of 1,751,699. The company has a quick ratio of 1.64, a current ratio of 2.15 and a debt-to-equity ratio of 0.34. The company’s fifty day moving average is $133.04 and its 200 day moving average is $138.22. Agilent Technologies, Inc. has a 52-week low of $96.80 and a 52-week high of $155.35. The stock has a market capitalization of $40.58 billion, a P/E ratio of 32.90, a P/E/G ratio of 4.86 and a beta of 1.05.

Agilent Technologies (NYSE:A) last announced its earnings results on Wednesday, May 29th. The medical research company reported $1.22 EPS for the quarter, beating the consensus estimate of $1.19 by $0.03. Agilent Technologies had a net margin of 18.84% and a return on equity of 26.25%. The company had revenue of $1.57 billion during the quarter, compared to the consensus estimate of $1.58 billion. During the same quarter in the prior year, the company posted $1.27 earnings per share. The firm’s revenue for the quarter was down 8.4% on a year-over-year basis. Sell-side analysts anticipate that Agilent Technologies, Inc. will post 5.24 earnings per share for the current fiscal year.

Agilent Technologies Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Wednesday, July 24th. Investors of record on Tuesday, July 2nd were given a dividend of $0.236 per share. This represents a $0.94 dividend on an annualized basis and a dividend yield of 0.68%. The ex-dividend date of this dividend was Tuesday, July 2nd. Agilent Technologies’s payout ratio is 22.22%.

Insider Buying and Selling

In other news, SVP Dominique Grau sold 15,000 shares of the stock in a transaction that occurred on Monday, June 10th. The shares were sold at an average price of $133.28, for a total transaction of $1,999,200.00. Following the completion of the transaction, the senior vice president now directly owns 49,486 shares of the company’s stock, valued at approximately $6,595,494.08. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In related news, SVP Dominique Grau sold 15,000 shares of the business’s stock in a transaction dated Monday, June 10th. The stock was sold at an average price of $133.28, for a total value of $1,999,200.00. Following the sale, the senior vice president now directly owns 49,486 shares in the company, valued at approximately $6,595,494.08. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Padraig Mcdonnell sold 1,958 shares of the company’s stock in a transaction dated Friday, July 26th. The shares were sold at an average price of $140.00, for a total transaction of $274,120.00. Following the sale, the chief executive officer now directly owns 26,076 shares in the company, valued at $3,650,640. The disclosure for this sale can be found here. Over the last three months, insiders have sold 18,916 shares of company stock worth $2,527,860. 0.33% of the stock is owned by company insiders.

Analyst Ratings Changes

A number of analysts have commented on A shares. Stifel Nicolaus cut their price target on shares of Agilent Technologies from $163.00 to $151.00 and set a “buy” rating on the stock in a research report on Thursday, May 30th. Jefferies Financial Group reissued a “hold” rating and set a $135.00 target price (down from $152.00) on shares of Agilent Technologies in a research note on Monday, June 3rd. Barclays dropped their price objective on shares of Agilent Technologies from $135.00 to $125.00 and set an “underweight” rating on the stock in a report on Friday, May 31st. Bank of America raised their target price on Agilent Technologies from $134.00 to $140.00 and gave the company a “neutral” rating in a research note on Tuesday, June 25th. Finally, Wolfe Research downgraded Agilent Technologies from an “outperform” rating to a “peer perform” rating in a research note on Thursday, June 27th. One research analyst has rated the stock with a sell rating, six have assigned a hold rating and ten have given a buy rating to the company. Based on data from MarketBeat, Agilent Technologies has an average rating of “Moderate Buy” and a consensus price target of $138.06.

Agilent Technologies Company Profile

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies.